✦ LIBER ✦

7137 Final analysis of a large open-label, noncomparative, phase 3 study of sorafenib in European patients with advanced RCC (EU-ARCCS)

✍ Scribed by Beck, J.; Procopio, I.; Negrier, S.; Keilholz, D.; Sczylik, C.; Bokemeyer, C.; Strauss, U.P.; Burock, K.; Mersmann, S.; Escudier, B.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

254 A SUBANALYSIS OF PATIENTS WITH AND W

✍ M. Staehler; G. Procopio; U. Keilholz; S. Negrier; C. Szczylik; J. Beck; U.P. St 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 506 KB

7132 Safety and efficacy of sorafenib in

✍ Bokemeyer, C.; Gore, M.; Bracarda, I.; Richel, N.; Staehler, D.; von der Maase, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

A LARGE OPEN-LABEL, NON-COMPARATIVE, PHA

✍ J. Beck; E. Verzoni; S. Negrier; U. Keilholz; C. Szczylik; S. Bracarda; C. Bokem 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 73 KB

4506 ORAL A large open-label, non-compar

✍ Beck, J.; Bajetta, E.; Escudier, B.; Negrier, S.; Keilholz, U.; Szczylik, C.; Me 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 59 KB